Abstract
Fast evaluation of vaccine effectiveness (VE) is valuable for facilitating vaccine development and making vaccination strategy. In previous studies, we developed the computational model linking molecular variations and VE for the influenza and COVID-19, through which VE prediction prior to mass vaccination and infection is possible. In this study, we perform a complete survey of the predictive effect of major functional regions of the influenza virus for VE. Interestingly, we found that the genetic distance measured on the antigenic sites being also the effective mutations for epidemics is a strong predictor for influenza VE. Based on the identified optimal predictor codon set, we develop the improved VE-Genetic Distance model for influenza (VE-GD flu). The prediction accuracy of the new model is R-square 87.1% for H3N2 (p-value < 0.001) on VE data of the United States. Leave-one-out cross validation shows that the concordance correlation coefficient of the predicted and observed VE is 90.6% (95% CI: 73.8-96.9). Significant prediction improvement is also found for pH1N1. Accurate prediction of influenza VE before vaccine deployment may facilitate reverse vaccinology to optimize vaccine antigen design and government preparedness of influenza epidemics.
Competing Interest Statement
M.H.W and B.C.Y.Z are shareholders of Beth Bioinformatics Co., Ltd. B.C.Y.Z is a shareholder of Health View Bioanalytics Ltd. All other authors declare no competing interests.
Funding Statement
This work was partially supported by the Strategic Seed Funding for Collaborative Research Scheme [3136001], the Chinese University of Hong Kong Direct Grant [2022.02], and NSFC Excellent Young Scientists Fund [32322088].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
In this revision, the main text is rewritten. The figures and findings are almost the same.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
